IL2 and breast carcinoma: For example, a preclinical study showed that in a mouse breast cancer model, lipid-coated biodegradable hollow MSNs co-loaded with interleukin-2 (IL-2), doxorubicin (DOX), and all-trans retinoic acid (ATRA) markedly improved antitumor immunity.